Biased agonism of endogenous opioid peptides at the μ-opioid receptor

Molecular Pharmacology

Volumn 88, Issue 2, 2015, Pages 335-346

  Thompson, Georgina L ^a,b   Lane, J Robert ^a   Coudrat, Thomas ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a   Canals, Meritxell ^a  

^a MONASH UNIVERSITY   (Australia)

^b DEFENCE SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA-NEOENDORPHIN; ENDOMORPHIN 1; ENDORPHIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; MU OPIATE RECEPTOR; OLIGOPEPTIDE; OPIATE PEPTIDE; PROTEIN PRECURSOR;

AGONISTS; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; METABOLISM; PRINCIPAL COMPONENT ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; CHO CELLS; CRICETULUS; ENDORPHINS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GTP-BINDING PROTEINS; OLIGOPEPTIDES; OPIOID PEPTIDES; PRINCIPAL COMPONENT ANALYSIS; PROTEIN PRECURSORS; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 84939782540     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.098848     Document Type: Article

References (69)

1. Al-Hasani R and Bruchas MR (2011) Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 115:1363-1381.
2. Arden JR, Segredo V, Wang Z, Lameh J, and Sadée W (1995) Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged μ-opioid receptor expressed in HEK 293 cells. J Neurochem 65:1636-1645.
3. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, and Vallejo R (2008) Opioid complications and side effects. Pain Physician 11(2, Suppl)S105-S120.
4. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
5. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, and Barak LS (2004) Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66:106-112.
6. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, and Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498.
7. Chen Y-J, Oldfield S, Butcher AJ, Tobin AB, Saxena K, Gurevich VV, Benovic JL, Henderson G, and Kelly E (2013) Identification of phosphorylation sites in the COOH-terminal tail of the μ-opioid receptor. J Neurochem 124:189-199.
8. Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19:351-357.
9. Clark MJ, Furman CA, Gilson TD, and Traynor JR (2006) Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther 317:858-864.
10. Cox BM, Christie MJ, Devi L, Toll L, and Traynor JR (2015) Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol 172:317-323.
11. DeWire SM, Ahn S, Lefkowitz RJ, and Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
12. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, and Yuan C et al. (2013) A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344:708-717.
13. Doll C, Konietzko J, Pöll F, Koch T, Höllt V, and Schulz S (2011) Agonist-selective patterns of μ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 164:298-307.
14. Fichna J, Janecka A, Costentin J, and Do Rego J-C (2007) The endomorphin system and its evolving neurophysiological role. Pharmacol Rev 59:88-123.
15. Frölich N, Dees C, Paetz C, Ren X, Lohse MJ, Nikolaev VO, and Zenk MH (2011) Distinct pharmacological properties of morphine metabolites at G(i)-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor. Biochem Pharmacol 81:1248-1254.
16. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, and Luttrell LM (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1:1ra1.
17. Goldberg IE, Rossi GC, Letchworth SR, Mathis JP, Ryan-Moro J, Leventhal L, Su W, Emmel D, Bolan EA, and Pasternak GW (1998) Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286:1007-1013.
18. Groer CE, Schmid CL, Jaeger AM, and Bohn LM (2011) Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J Biol Chem 286:31731-31741.
19. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, and Bohn LM (2007) An opioid agonist that does not induce mu-opioid receptor - arrestin interactions or receptor internalization. Mol Pharmacol 71:549-557.
20. Janecka A, Fichna J, and Janecki T (2004) Opioid receptors and their ligands. Curr Top Med Chem 4:1-17.
21. Jiang LI, Collins J, Davis R, Lin KM, DeCamp D, Roach T, Hsueh R, Rebres RA, Ross EM, and Taussig R et al. (2007) Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J Biol Chem 282:10576-10584.
22. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
23. Kelly E (2013) Ligand bias at the μ-opioid receptor. Biochem Soc Trans 41:218-224.
24. Kenakin T and Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:205-216.
25. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203.
26. Lau EK, Trester-Zedlitz M, Trinidad JC, Kotowski SJ, Krutchinsky AN, Burlingame AL, and von Zastrow M (2011) Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Sci Signal 4:ra52.
27. Leff P, Prentice DJ, Giles H, Martin GR, and Wood J (1990) Estimation of agonist affinity and efficacy by direct, operational model-fitting. J Pharmacol Methods 23:225-237.
28. Lonergan T, Goodchild AK, Christie MJ, and Pilowsky PM (2003) Mu opioid receptors in rat ventral medulla: effects of endomorphin-1 on phrenic nerve activity. Respir Physiol Neurobiol 138:165-178.
29. Macey TA, Bobeck EN, Hegarty DM, Aicher SA, Ingram SL, and Morgan MM (2006) Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat. J Pharmacol Exp Ther 331:412-418.
30. Maguma HT, Dewey WL, and Akbarali HI (2012) Differences in the characteristics of tolerance to μ-opioid receptor agonists in the colon from wild type and β-arrestin2 knockout mice. Eur J Pharmacol 685:133-140.
31. Mansour A, Hoversten MT, Taylor LP, Watson SJ, and Akil H (1995) The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res 700:89-98.
32. Massotte D, Brillet K, Kieffer B, and Milligan G (2002) Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently. J Neurochem 81:1372-1382.
33. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, and Dollé P et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819-823.
34. McConalogue K, Grady EF, Minnis J, Balestra B, Tonini M, Brecha NC, Bunnett NW, and Sternini C (1999) Activation and internalization of the μ-opioid receptor by the newly discovered endogenous agonists, endomorphin-1 and endomorphin-2. Neuroscience 90:1051-1059.
35. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey CP, Rosethorne EM, and Charlton SJ et al. (2010) μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78:756-766.
36. Miyatake M, Rubinstein TJ, McLennan GP, Belcheva MM, and Coscia CJ (2009) Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways. J Neurochem 110:662-674.
37. Molinari P, Vezzi V, Sbraccia M, Grò C, Riitano D, Ambrosio C, Casella I, and Costa T (2010) Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem 285:12522-12535.
38. Morse M, Tran E, Sun H, Levenson R, and Fang Y (2011) Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target. PLoS ONE 6:e25643.
39. Motulsky HJ and Ransnas LA (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1:365-374.
40. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, Strachan RT, Huang TY, Bressler EA, and Hara MR et al. (2011) Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci Signal 4:ra51.
41. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R, and Dubourg V et al. (2011) Scikit-learn: Machine Learning in Python. J Mach Learn Res 12:2825-2830.
42. Pradhan AA, Smith ML, Kieffer BL, and Evans CJ (2012) Ligand-directed signalling within the opioid receptor family. Br J Pharmacol 167:960-969.
43. Raehal KM, Schmid CL, Groer CE, and Bohn LM (2011) Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63:1001-1019.
44. Raehal KM, Walker JK, and Bohn LM (2005) Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195-1201.
45. Rajagopal S, Bassoni DL, Campbell JJ, Gerard NP, Gerard C, and Wehrman TS (2013) Biased agonism as a mechanism for differential signaling by chemokine receptors. J Biol Chem 288:35039-35048.
46. Rivero G, Llorente J, McPherson J, Cooke A, Mundell SJ, McArdle CA, Rosethorne EM, Charlton SJ, Krasel C, and Bailey CP et al. (2012) Endomorphin-2: a biased agonist at the μ-opioid receptor. Mol Pharmacol 82:178-188.
47. Saidak Z, Blake-Palmer K, Hay DL, Northup JK, and Glass M (2006) Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol 147:671-680.
48. Sakurada S, Hayashi T, and Yuhki M (2002) Differential antinociceptive effects induced by intrathecally-administered endomorphin-1 and endomorphin-2 in mice. Jpn J Pharmacol 89:221-223.
49. Sánchez-Blázquez P, Gómez-Serranillos P, and Garzón J (2001) Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull 54:229-235.
50. Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, and Höllt V (2004) Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J 23:3282-3289.
51. Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, and Webster LR (2014) Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155:1829-1835.
52. Terashvili M, Wu HE, Schwasinger E, and Tseng LF (2007) Paradoxical hyperalgesia induced by mu-opioid receptor agonist endomorphin-2, but not endomorphin-1, microinjected into the centromedial amygdala of the rat. Eur J Pharmacol 554:137-144.
53. Thompson GL, Kelly E, Christopoulos A, and Canals M (2015) Novel GPCR paradigms at the μ-opioid receptor. Br J Pharmacol 172:287-296.
54. Tonini M, Fiori E, Balestra B, Spelta V, D'Agostino G, Di Nucci A, Brecha NC, and Sternini C (1998) Endomorphin-1 and endomorphin-2 activate μ-opioid receptors in myenteric neurons of the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 358:686-689.
55. Traynor J (2012) μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 121:173-180.
56. Valant C, May LT, Aurelio L, Chuo CH, White PJ, Baltos JA, Sexton PM, Scammells PJ, and Christopoulos A (2014) Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc Natl Acad Sci USA 111:4614-4619.
57. Viganò D, Rubino T, Di Chiara G, Ascari I, Massi P, and Parolaro D (2003) Mu opioid receptor signaling in morphine sensitization. Neuroscience 117:921-929.
58. Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, and Lefkowitz RJ (2009) beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 119:1312-1321.
59. Whistler JL and von Zastrow M (1998) Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 95:9914-9919.
60. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, and Christie MJ (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65:223-254.
61. Willoughby D and Cooper DM (2007) Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 87:965-1010.
62. Wold S, Esbensen K, and Geladi P (1987) Principal component analysis. Chemom Intell Lab Syst 2:37-52.
63. Yu Y, Cui Y, Wang X, Lai LH, Wang C-L, Fan YZ, Liu J, and Wang R (2007) In vitro characterization of the effects of endomorphin 1 and 2, endogenous ligands for μ-opioid receptors, on mouse colonic motility. Biochem Pharmacol 73:1384-1393.
64. Zadina JE, Hackler L, Ge LJ, and Kastin AJ (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature 386:499-502.
65. Zaki PA, Keith DE, Jr, Brine GA, Carroll FI, and Evans CJ (2000) Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 292:1127-1134.
66. Zhao P, Canals M, Murphy JE, Klingler D, Eriksson EM, Pelayo JC, Hardt M, Bunnett NW, and Poole DP (2013) Agonist-biased trafficking of somatostatin receptor 2A in enteric neurons. J Biol Chem 288:25689-25700.
67. Zheng H, Loh HH, and Law PY (2008) Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation. Mol Pharmacol 73:178-190.
68. Zidar DA (2011) Endogenous ligand bias by chemokines: implications at the front lines of infection and leukocyte trafficking. Endocr Metab Immune Disord Drug Targets 11:120-131.
69. Zidar DA, Violin JD, Whalen EJ, and Lefkowitz RJ (2009) Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA 106:9649-9654.